CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.55BUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.30xvs all stocks
52-Week Change
54.01%vs all stocks
Market Capitalization
1.55BUSDvs all stocks (USD)
Enterprise Value
1.21BUSDvs all stocks (USD)
Forward P/E
-9.06xvs Biotechnology peers
Price to Book (MRQ)
4.43xvs Biotechnology peers
Enterprise to EBITDA
-6.81xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-34.72%vs Biotechnology peers
Return on Equity (TTM)
-55.17%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 18, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
0.00USDvs all stocks (USD)
Net Income (TTM)
-145.24MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-134.47MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-82.84MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-177.53MUSDvs all stocks (USD)
Pre-tax Income
-166.31MUSDFY2025 · Dec 31, 2025Net Income
-166.31MUSDFY2025 · Dec 31, 2025EBIT
-177.53MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-177.53MUSDFY2025 · Dec 31, 2025Research & Development
153.35MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
24.18MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
11.23MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-166.31MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-154.69MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
45.54MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-166.31MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.52MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-3.03MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.14MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-21.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-272.93MUSDFY2025 · Dec 31, 2025Sale of Investments
201.71MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-71.23MUSDFY2025 · Dec 31, 2025Other Financing Charges
-70.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
202.56MUSDFY2025 · Dec 31, 2025Shares Outstanding
45.31MSharesUpdated Jul 18, 2026Float Shares
29.78MSharesUpdated Jul 18, 2026Shares Short
7.62MSharesUpdated Jul 18, 2026Short Ratio
10.56daysvs all stocks
Short % of Shares Outstanding
17.43%vs all stocks
% Held by Insiders
1.63%vs all stocks
% Held by Institutions
96.00%vs all stocks
Total Cash (MRQ)
326.38MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.01USDUpdated Jul 18, 2026Total Debt (MRQ)
419.00KUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0013xvs Biotechnology peers
Current Ratio (MRQ)
13.95xvs Biotechnology peers
Book Value per Share (MRQ)
7.15USDUpdated Jul 18, 2026Total Assets
333.17MUSDvs all stocks (USD)
Total Current Assets
332.90MUSDFY2025 · Dec 31, 2025Total Liabilities
25.95MUSDFY2025 · Dec 31, 2025Total Non-current Assets
272.00KUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
0.00USDFY2025 · Dec 31, 2025Total Current Liabilities
25.95MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.54MUSDFY2025 · Dec 31, 2025Other Short-term Investments
267.28MUSDFY2025 · Dec 31, 2025Accounts Payable
5.93MUSDFY2025 · Dec 31, 2025Short-term Debt
14.00KUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Common Stock (Book)
4.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-404.64MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
307.22MUSDvs all stocks (USD)
52-Week Low
16.10USDUpdated Jul 18, 202652-Week High
35.83USDUpdated Jul 18, 202652-Week Change
54.01%vs all stocks
Beta
1.30xvs all stocks
50-Day MA
30.82USDUpdated Jul 18, 2026200-Day MA
24.66USDUpdated Jul 18, 2026Avg 10-Day Volume
405.78KSharesUpdated Jul 18, 2026Avg 30-Day Volume
579.13KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-3.38USDUpdated Jul 18, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Market cap is $1.55B, above the global median of $1.15BNotable
Market cap (USD): 1,545,821,860Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Classys Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maze Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Green Thumb Industries Inc.
Tier 1ProductionApproval-Gated PipelineFlowRule
Enovis Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hualan Biological Engineering Inc.
Tier 1ProductionApproval-Gated PipelineRule
Recursion Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tianjin Chase Sun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Marksans Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Forte Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule